Overview

Inhibitors of the PCSK9 protein represent an important new therapeutic class for patients with familiar hypercholesterolemia or established CVD who require further LDL-C lowering beyond what statins can provide. This Case Curriculum illustrates two patient scenarios for the use of PCSK9 inhibitors, and reviews selection of patients who require more intensive LDL-C lowering and clinical efficacy and safety data for these novel agents.

Learning Objectives

  • Outline the differences between the 2013 AHA/ACC guideline recommendations and those from other hypercholesterolemia treatment guidelines.
  • Implement optimal medical therapy for patients with hypercholesterolemia based on the latest guideline recommendations and clinical data.
  • Discuss the role of PCSK9 in LDL-C metabolism and as a therapeutic target for the treatment of hypercholesterolemia.
  • Evaluate recent clinical trial data and the role of PCSK9 inhibitors in reducing cardiovascular risk among various patient groups with hypercholesterolemia.

Courses

Disclosures

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

Faculty Disclosures

P. Barton Duell, MD

Speakers Bureau for Genzyme and sanofi-aventis U.S. Contracted Research for Genzyme; sanofi-aventis U.S.; and Retrophin, Inc. Consultant for Genzyme; Kaneka Corporation; Lilly, Retrophin, Inc.; and sanofi-aventis U.S. 

James A. Underberg, MD, MS, FACPM, FACP, FNLA

Speakers Bureau for Aegerion Pharmaceuticals Inc.; Alexion Pharmaceuticals; Amgen, Inc; AstraZeneca; Genzyme; Merck & Co., Inc.; and sanofi-aventis U.S. Medical Advisory Board for Aegerion Pharmaceuticals Inc.; Akcea Therapeutics; Amgen, Inc.; Genzyme; Lilly; and sanofi-aventis U.S. Contracted Research for Aegerion Pharmaceuticals Inc. and Pfizer, Inc. Consultant for Amgen, Inc. and Amarin Corporation.

From Horizon CME, Brian Lee, PharmD, and Cara Williams, PharmD, have no relevant relationships to disclose.


Commercial Supporters

sanofi-aventis U.S. and Regeneron Pharmaceuticals.

Education Partner

Horizon CME


Fine Print

Internet Explorer (version 9.0 and above) is the minimum supported browser for Pri-Med Online eCME activities. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection (DSL, cable modem, or LAN-based) is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC, or Vindico Medical Education.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.

Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation. pmiCME and Vindico Medical Education staff have no relevant financial relationships to disclose.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.